- Home
- ABOS vs CNTB Comparison
ABOS vs CNTB Comparison
Compare ABOS & CNTB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ABOS | CNTB |
|---|---|---|
| Founded | 1996 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 165.6M | 140.4M |
| IPO Year | 2021 | 2020 |
Fundamental Metrics
Financial Performance| Metric | ABOS | CNTB |
|---|---|---|
| Price | $0.22 | $0.72 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 6 | 7 |
| Target Price | $1.00 | ★ $6.00 |
| AVG Volume (30 Days) | ★ 4.9M | 949.9K |
| Earning Date | 10-26-2026 | 11-20-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $64,000.00 |
| Revenue This Year | N/A | $11,287.85 |
| Revenue Next Year | N/A | $74.11 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.20 | $0.73 |
| 52 Week High | $3.60 | $3.82 |
Technical Indicators
Market Signals| Indicator | ABOS | CNTB |
|---|---|---|
| Relative Strength Index (RSI) | 20.55 | 35.56 |
| Support Level | N/A | N/A |
| Resistance Level | $2.66 | $2.62 |
| Average True Range (ATR) | 0.16 | 0.07 |
| MACD | -0.18 | 0.02 |
| Stochastic Oscillator | 1.06 | 10.67 |
Price Performance
Historical ComparisonAbout ABOS Acumen Pharmaceuticals Inc.
Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what it believes to be a key underlying cause of Alzheimer's disease. The company's drug candidate, ACU193, is a subclass monoclonal antibody that selectively targets amyloid-beta oligomers. The product pipelines include: ALTITUDE-AD; and INTERCEPT-AD.
About CNTB Connect Biopharma Holdings Limited
Connect Biopharma Holdings Ltd is a clinical-stage biopharmaceutical company dedicated to transforming care for asthma and chronic obstructive pulmonary disease (COPD). The company is advancing rademikibart, a next-generation antibody designed to target interleukin-4-receptor alpha. It is currently conducting clinical studies of rademikibart for the treatment of acute exacerbations of asthma and COPD. The company operates in one operating segment: treatment of respiratory diseases.